A Portfolio Analysis and Innovation Policy Taiwan’s Protein Chips and Lab-on-a-chip Industries

• Main Authors: Chen, Chia-ling, 陳佳伶
• Other Authors: Joseph Z. Shyu
• Format: Others
• Language: zh-TW
• Published: 2002
• Online Access: http://ndltd.ncl.edu.tw/handle/31722820896014009928

碩士 === 國立交通大學 === 科技管理所 === 90 === Taiwan’s biotech Industry has been selected as one of the ten emerging industries to receive preferential assistance by the government. The biochip Industry is a newly developed area with a promising potential. This thesis reports a strategic analysis on the development of Taiwan’s biochip industry, including protein chips and lab-on-a-chip. A portfolio model is used to assess competitive and strategic requirements for the development. An attempt is also made to provide policy recommendations, as demanded by industrial firms, to the government. The portfolio model entails a 2-dimensional analysis, containing Taiwan’s technology s-curve (vertical axis) and the supply chain (horizontal axis). Three research methods are used for data collection, which include literature review, expert interview, and general survey. The protein chips and lab-on-a-chip are positioned at the burgeoning phase of the biochip’s technology s-curve and the fundamental research stage of biochip industry supply chain. In Taiwan, there are few companies aiming at developing protein chips for diseases specific to the Taiwanese. Only few universities and research institutions in Taiwan have invested in R&D for lab-on-a-chip. This research reveals that the technical capability of the biochips must be prefereatively developed before competing globally against foreign firms. This research uses the Industrial Portfolio model to evaluate the Industrial Innovation Requirements and Policy Tools necessary for the development of Taiwan’s biochip industry. The policy categories of greater importance are Scientific/Technical Development and Financial. This research recommends that Taiwan establish cross-disciplinary research laboratories, incubators, biotech industrial parks, and proteomic centers to expedite the developments, accumulation, diffusion and applications of knowledge in the industry. Moreover, government grants, bank loans, venture capital funds, and corporate finance should be the preferred financial policy instruments available to biochip research institutions and biotech companies.